Advances in the molecular characterization of melanoma and BRAFV600E mutant protein and better knowledge of the BRAF signaling cascade have enabled the development of therapeutic BRAF-kinase inhibitors that target the constitutively active mutant BRAF protein. This evidence concerns the gene BRAF and melanoma.